ArticleFrontiers in pharmacology2023

Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series.

Hisham Ibrahim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.